Previous close | 11.15 |
Open | 11.15 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 11.14 - 11.14 |
52-week range | 10.07 - 11.80 |
Volume | |
Avg. volume | 13,927 |
Market cap | 100.162M |
Beta (5Y monthly) | -0.00 |
PE ratio (TTM) | 48.43 |
EPS (TTM) | 0.23 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Tarrytown, NY and New York, NY, Jan. 29, 2024 (GLOBE NEWSWIRE) -- PowerUp Acquisition Corp. (“PowerUp”) (Nasdaq: PWUP) and Visiox Pharmaceuticals, Inc. (“Visiox”), a commercial-stage biopharmaceutical company, today announced that PowerUp has filed with the U.S. Securities and Exchange Commission (“SEC”) a registration statement on Form S-4 in connection with the previously announced proposed business combination between PowerUp and Visiox (the “Business Combination” or the “Transaction”). The c
Tarrytown, NY and New York, NY, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Visiox Pharmaceuticals, Inc. (“Visiox” or the “Company”), a commercial-stage biopharmaceutical company, and PowerUp Acquisition Corp. (“PowerUp”) (Nasdaq: PWUP) today announced the execution of a definitive agreement for a business combination (the “Transaction” or the “Business Combination”) that would result in Visiox becoming a publicly traded company on the Nasdaq Capital Market (“Nasdaq”). The business combination is expected
Key Insights Significant control over PowerUp Acquisition by individual investors implies that the general public has...